Alkermes   2Q Revenues: $138.6 million (-9%)   2Q Earnings: $7.3 million (earnings were $22.4 million 2Q12)   Comments: Revenues from the company’s five key commercial products for the quarter grew 22% to $98.9 million. Manufacturing and royalty revenues from Risperdal Consta and Invega Sustenna/Xeplion were $56.2 million, up 16%. Manufacturing and royalty revenues from Ampyra/Fampyra were $19.9 million, up 16%. Net sales of Vivitrol were $17.4 million, up 40%. Royalty revenue from Bydureon was ...